Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow up. Data from the study show clear overall improvements in vision and cognition for participants treated for nearly three years from randomization, with these results robust and consistent, according to Professor Michael Barnett, Professor of Neurology, Brain and Mind Centre, University of Sydney, and one of the trial’s key clinical advisors. “Clene is closely studying CNM-Au8(R) because a drug that may halt MS disease progression and may even improve function on top of standard-of-care MS therapies would represent a milestone achievement in drug development for this disease,” a recent article reads. “These data continue to build a strong case in favor of pursuing CNM-Au8 in upcoming Phase 3 studies. Clinically significant improvement is rarely seen in MS patients, and this trial provides evidence of CNM-Au8’s potential to improve function in this population,” Dr. Benjamin Greenberg, M.D., Head of Medicine at Clene, is quoted as saying.
To view the full article, visit https://ibn.fm/63mVz
About Clene Inc.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com